Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma.

Wenzina J, Holzner S, Puujalka E, Cheng PF, Forsthuber A, Neumüller K, Schossleitner K, Lichtenberger BM, Levesque MP, Petzelbauer P.

J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)33299-3. doi: 10.1016/j.jid.2019.08.451. [Epub ahead of print]

PMID:
31622599
2.

A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.

Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, Arafeh R, Goldin V, Levesque MP, Peeper DS, Samuels Y.

Pigment Cell Melanoma Res. 2019 Sep 24. doi: 10.1111/pcmr.12825. [Epub ahead of print]

PMID:
31549767
3.

Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis.

Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, Janssens D, Henikoff S, Eisenman RN.

Genes Dev. 2019 Sep 1;33(17-18):1252-1264. doi: 10.1101/gad.325878.119. Epub 2019 Aug 8.

PMID:
31395740
4.

Exogenic glucose as an electron donor for algal hydrogenases to promote hydrogen photoproduction by Chlorella pyrenoidosa.

Liu JZ, Ge YM, Sun JY, Chen P, Addy M, Huo SH, Li K, Cheng PF, Ruan R.

Bioresour Technol. 2019 Oct;289:121762. doi: 10.1016/j.biortech.2019.121762. Epub 2019 Jul 6.

PMID:
31311731
5.

Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP.

EMBO J. 2019 Aug 1;38(15):e95874. doi: 10.15252/embj.201695874. Epub 2019 Jun 26.

PMID:
31267558
6.

Melanoma patients with additional primary cancers: a single-center retrospective analysis.

Dimitriou F, Mangana J, Curioni-Fontecedro A, Rechsteiner M, Turko P, Braun RP, Dummer R, Cheng PF.

Oncotarget. 2019 May 21;10(36):3373-3384. doi: 10.18632/oncotarget.26931. eCollection 2019 May 21.

7.

A novel financial risk assessment model for companies based on heterogeneous information and aggregated historical data.

Li DP, Cheng SJ, Cheng PF, Wang JQ, Zhang HY.

PLoS One. 2018 Dec 26;13(12):e0208166. doi: 10.1371/journal.pone.0208166. eCollection 2018.

8.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
9.

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):686-692. doi: 10.1111/jdv.15363. Epub 2018 Dec 13.

PMID:
30468696
10.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP.

Cancer Immunol Res. 2019 Jan;7(1):77-85. doi: 10.1158/2326-6066.CIR-18-0136. Epub 2018 Nov 13.

PMID:
30425105
11.

Enhancing Astaxanthin Accumulation in Haematococcus pluvialis by Coupled Light Intensity and Nitrogen Starvation in Column Photobioreactors.

Zhang WW, Zhou XF, Zhang YL, Cheng PF, Ma R, Cheng WL, Chu HQ.

J Microbiol Biotechnol. 2018 Dec 28;28(12):2019-2028. doi: 10.4014/jmb.1807.07008.

12.

Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.

Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):667-675. doi: 10.1111/jdv.15302. Epub 2018 Nov 26.

PMID:
30357969
13.

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L.

Cancer Cell. 2018 Jul 9;34(1):69-84.e14. doi: 10.1016/j.ccell.2018.06.001. Epub 2018 Jun 28.

14.

[Purification Effect of Piggery Wastewater with Chlorella pyrenoidosa by Immobilized Biofilm-Attached Culture].

Wang YZ, Cheng PF, Liu DF, Liu TZ.

Huan Jing Ke Xue. 2017 Aug 8;38(8):3354-3361. doi: 10.13227/j.hjkx.201701113. Chinese.

PMID:
29964944
15.

Unexpected invasion of miniature inverted-repeat transposable elements in viral genomes.

Zhang HH, Zhou QZ, Wang PL, Xiong XM, Luchetti A, Raoult D, Levasseur A, Santini S, Abergel C, Legendre M, Drezen JM, Béliveau C, Cusson M, Jiang SH, Bao HO, Sun C, Bureau TE, Cheng PF, Han MJ, Zhang Z, Zhang XG, Dai FY.

Mob DNA. 2018 Jun 18;9:19. doi: 10.1186/s13100-018-0125-4. eCollection 2018.

16.

Melanoma Immunotherapy: Next-Generation Biomarkers.

Hogan SA, Levesque MP, Cheng PF.

Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018. Review.

17.

Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.

Häfliger EM, Ramelyte E, Mangana J, Kunz M, Kazakov DV, Dummer R, Cheng PF.

Melanoma Res. 2018 Oct;28(5):442-450. doi: 10.1097/CMR.0000000000000465.

PMID:
29847461
18.

Methadone-Not a magic bullet in melanoma therapy.

Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R.

Exp Dermatol. 2018 Jun;27(6):694-696. doi: 10.1111/exd.13543.

PMID:
29577418
19.

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V.

Clin Proteomics. 2018 Mar 9;15:13. doi: 10.1186/s12014-018-9189-x. eCollection 2018.

20.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Erratum in: Cancer Discov. 2018 Dec;8(12):1654.

21.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

22.

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2018 Jan 22;9(1):314. doi: 10.1038/s41467-018-02850-8.

23.

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.

Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, Horak C, Levesque M, Dummer R, Cheng PF.

Neoplasia. 2018 Feb;20(2):218-225. doi: 10.1016/j.neo.2017.12.002. Epub 2018 Jan 12.

24.

Medical bioinformatics in melanoma.

Cheng PF.

Curr Opin Oncol. 2018 Mar;30(2):113-117. doi: 10.1097/CCO.0000000000000428. Review.

PMID:
29227308
25.

low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L.

Nat Commun. 2017 Dec 7;8(1):1988. doi: 10.1038/s41467-017-01573-6. Erratum in: Nat Commun. 2018 Jan 22;9(1):314.

26.

Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X.

Nat Chem Biol. 2018 Jan;14(1):94-101. doi: 10.1038/nchembio.2510. Epub 2017 Oct 30.

PMID:
29083417
27.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

28.

Sox2 is dispensable for primary melanoma and metastasis formation.

Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, Dummer R, Nicolis SK, Sommer L.

Oncogene. 2017 Aug;36(31):4516-4524. doi: 10.1038/onc.2017.55. Epub 2017 Apr 3.

29.

Metastatic melanoma moves on: translational science in the era of personalized medicine.

Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R.

Cancer Metastasis Rev. 2017 Mar;36(1):7-21. doi: 10.1007/s10555-017-9658-0. Review.

PMID:
28321632
30.

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM.

Melanoma Res. 2017 Jun;27(3):231-237. doi: 10.1097/CMR.0000000000000338.

31.

Predicting Air Quality at First Ingress into Vehicles Visiting the International Space Station.

Romoser AA, Scully RR, Limero TF, De Vera V, Cheng PF, Hand JJ, James JT, Ryder VE.

Aerosp Med Hum Perform. 2017 Feb 1;88(2):104-113. doi: 10.3357/AMHP.4702.2017.

PMID:
28095954
32.

Myc/Mycn-mediated glycolysis enhances mouse spermatogonial stem cell self-renewal.

Kanatsu-Shinohara M, Tanaka T, Ogonuki N, Ogura A, Morimoto H, Cheng PF, Eisenman RN, Trumpp A, Shinohara T.

Genes Dev. 2016 Dec 1;30(23):2637-2648. doi: 10.1101/gad.287045.116.

33.

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP.

Oncotarget. 2016 Nov 22;7(47):77163-77174. doi: 10.18632/oncotarget.12848.

34.

An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.

Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R.

Br J Dermatol. 2016 Nov;175(5):966-978. doi: 10.1111/bjd.14727. Epub 2016 Sep 19.

35.

[Coupling of Hydrocarbon Accumulation and Cobalt Removal During Treatment of Cobalt Enriched Industrial Wastewater with Botryococcus braunii Biofilm Attached Cultivation].

Cheng PF, Wang Y, Yang QY, Tang M, Liu TZ.

Huan Jing Ke Xue. 2016 Jul 8;37(7):2666-2672. doi: 10.13227/j.hjkx.2016.07.033. Chinese.

PMID:
29964477
36.

[The Fluorescence Detection of Oil Pollutants Based on Self-Weighted Alternating Trilinear Decomposition].

Cheng PF, Wang YT, Chen ZK, Yang Z, Cao LF.

Guang Pu Xue Yu Guang Pu Fen Xi. 2016 Jul;36(7):2162-8. Chinese.

PMID:
30035921
37.

[Research on Spectroscopy Spectrum De-Noising of Mineral Oil Based on Lifting Scheme Wavelet Transform].

Wang YT, Yang Z, Hou PG, Cheng PF, Cao LF.

Guang Pu Xue Yu Guang Pu Fen Xi. 2016 Jul;36(7):2144-7. Chinese.

PMID:
30035914
38.

Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.

Kim DW, Wu N, Kim YC, Cheng PF, Basom R, Kim D, Dunn CT, Lee AY, Kim K, Lee CS, Singh A, Gazdar AF, Harris CR, Eisenman RN, Park KS, MacPherson D.

Genes Dev. 2016 Jun 1;30(11):1289-99. doi: 10.1101/gad.279307.116.

39.

Investigation of Ramsey spectroscopy in a lin-par-lin Ramsey coherent population trapping clock with dispersion detection.

Sun XL, Zhang JW, Cheng PF, Xu C, Zhao L, Wang LJ.

Opt Express. 2016 Mar 7;24(5):4532-4541. doi: 10.1364/OE.24.004532.

PMID:
29092280
40.

Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.

Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C.

Curr Opin Oncol. 2016 Mar;28(2):172-9. doi: 10.1097/CCO.0000000000000261. Review.

PMID:
26742019
41.

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R.

Clin Cancer Res. 2016 Apr 15;22(8):2020-31. doi: 10.1158/1078-0432.CCR-15-1435. Epub 2015 Dec 9.

42.

The glucose-sensing transcription factor MLX promotes myogenesis via myokine signaling.

Hunt LC, Xu B, Finkelstein D, Fan Y, Carroll PA, Cheng PF, Eisenman RN, Demontis F.

Genes Dev. 2015 Dec 1;29(23):2475-89. doi: 10.1101/gad.267419.115. Epub 2015 Nov 19.

43.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

44.

[A De-Noising Algorithm for Fluorescence Detection Signal of Mineral Oil in Water by SWT].

Wang YT, Cheng PF, Hou PG, Yang Z.

Guang Pu Xue Yu Guang Pu Fen Xi. 2015 May;35(5):1286-9. Chinese.

PMID:
26415445
45.

Data mining The Cancer Genome Atlas in the era of precision cancer medicine.

Cheng PF, Dummer R, Levesque MP.

Swiss Med Wkly. 2015 Sep 16;145:w14183. doi: 10.4414/smw.2015.14183. eCollection 2015. Review.

46.

Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study.

Liu ML, Zhang XT, Du XY, Fang Z, Liu Z, Xu Y, Zheng P, Xu XJ, Cheng PF, Huang T, Bai SJ, Zhao LB, Qi ZG, Shao WH, Xie P.

J Transl Med. 2015 Jul 14;13:226. doi: 10.1186/s12967-015-0540-y.

47.

Combined Metabolomics and Proteomics Analysis of Major Depression in an Animal Model: Perturbed Energy Metabolism in the Chronic Mild Stressed Rat Cerebellum.

Shao WH, Chen JJ, Fan SH, Lei Y, Xu HB, Zhou J, Cheng PF, Yang YT, Rao CL, Wu B, Liu HP, Xie P.

OMICS. 2015 Jul;19(7):383-92. doi: 10.1089/omi.2014.0164.

48.

Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.

Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF.

Mol Cancer Ther. 2015 Sep;14(9):2132-42. doi: 10.1158/1535-7163.MCT-15-0023-T. Epub 2015 Jun 26.

49.

In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.

Urosevic-Maiwald M, Barysch MJ, Cheng PF, Karpova MB, Steinert H, Okoniewski MJ, Dummer R.

Oncoimmunology. 2015 Jan 7;4(2):e988458. eCollection 2015 Feb. Erratum in: Oncoimmunology. 2016 Feb 17;5(1):e1104009.

50.

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.

Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raaijmakers MI, Goldinger SM, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP.

Genome Biol. 2015 Feb 22;16:42. doi: 10.1186/s13059-015-0594-4.

Supplemental Content

Loading ...
Support Center